Form 8-K - Current report:
SEC Accession No. 0001193125-25-112812
Filing Date
2025-05-05
Accepted
2025-05-05 16:26:23
Documents
14
Period of Report
2025-05-01
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d20698d8k.htm   iXBRL 8-K 43846
2 EX-3.2 d20698dex32.htm EX-3.2 262689
  Complete submission text file 0001193125-25-112812.txt   493945

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA lnth-20250501.xsd EX-101.SCH 2853
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE lnth-20250501_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lnth-20250501_pre.xml EX-101.PRE 11709
16 EXTRACTED XBRL INSTANCE DOCUMENT d20698d8k_htm.xml XML 3848
Mailing Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862
Business Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862 978 671-8001
Lantheus Holdings, Inc. (Filer) CIK: 0001521036 (see all company filings)

EIN.: 352318913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36569 | Film No.: 25913379
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)